Prometheus Laboratories Launches MASH Precis, a Purpose-Built Non-Invasive Test Designed to Support Evolving MASH PathwaysBlood-based test combines liver fibrosis staging and prognostic risk assessment to support patient identification, evaluation and management across MASH care pathways
Celltrion USA and Prometheus Laboratories Inc. Announce Sponsored Testing Collaboration on Anser IFX for ZYMFENTRA (infliximab-dyyb)Celltrion Testing Access Program Expands Availability of Therapeutic Drug Monitoring to Support Patient Transition to Subcutaneous Infliximab
